PLEASANTON, Calif., Nov. 11, 2010 /PRNewswire/ — Thoratec
Corporation (Nasdaq:
THOR), a world leader in device-based mechanical circulatory
support therapies to save, support and restore failing hearts, said
today it will be hosting an investor event on Tuesday, November 16
at the American Heart Association (AHA) Scientific Sessions
2010.
Gary F. Burbach, president and chief executive officer of
Thoratec, will be discussing highlights from data presentations
during AHA regarding the company’s HeartMate II® LVAS (Left
Ventricular Assist System), as well as a review of the company’s
bridge-to-transplantation post-approval study, which showed
survival of 90 percent at six months and 85 percent at one
year.
The presentation will begin promptly at 12:30 p.m., Central
Standard Time. The event will be webcast and accessible via the
company’s web site at www.thoratec.com, with a replay
available until Tuesday, November 23.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company’s products include the
HeartMate® LVAS and Thoratec® VAD (Ventricular Assist
Device) with more than 15,000 devices implanted in patients
suffering from heart failure. Thoratec is headquartered in
Pleasanton, California. For more information, visit the company’s
web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are
registered trademarks of Thoratec Corporation and IVAD is a
trademark of Thoratec Corporation.
‘/>”/>
